G. Pussard et al., ENDOTHELIN-1 MODULATES CYCLIC-GMP PRODUCTION AND RELAXATION IN HUMAN PULMONARY VESSELS, The Journal of pharmacology and experimental therapeutics, 274(2), 1995, pp. 969-975
The aim of this study was to examine the effects of endothelin-1 (ET-1
) on sodium nitroprusside (SNP) induced relaxation and cyclic 3',5'-gu
anosine monophosphate (cGMP) accumulation in human pulmonary vessels.
The basal levels of cGMP were similar in arteries (2.48 +/- 0.24 pmol/
mg protein; n = 7) and veins (3.25 +/- 0.24 pmol/mg protein; n = 7). I
n tissues (n = 7) treated with N-omega-nitro-L-arginine and indomethac
in, cGMP values were significantly reduced (arteries, 1.30 +/- 0.24 pm
ol/mg protein and veins, 1.95 +/- 0.28 pmol/mg protein). In treated ti
ssues, SNP (10 mu M) increased the cGMP level by 10-fold in arteries a
nd veins. ET-1 (0.02 and 0.2 mu M) reduced significantly the cGMP incr
ease in SNP-stimulated vessels. This inhibition was greater in veins (
76%) when compared with arteries (34%). Norepinephrine (10 mu M) did n
ot affect the cGMP levels. The sensitivity and the maximal relaxation
induced by SNP in veins contracted with ET-1 (0.2 mu M) was significan
tly diminished (in comparison with norepinephrine; 10 mu M). In arteri
es, SNP relaxations were not altered by ET-1 contraction. Inasmuch as
8-bromo-cyclic 3',5' guanosine monophosphate curves were not altered b
y ET-1 treatment in either arteries or veins, the relaxant mechanisms
that are downstream of guanylate cyclase activation apparently are not
affected. These results suggest that ET-1 may play a role in the cont
rol of muscle tone in the human pulmonary vascular bed by modifying cG
MP levels associated with vasorelaxant agonist stimulation.